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A B S T R A C T
A 60-year-old man was admitted to our hospital with non-small cell lung cancer (NSCLC). Imaging and pa-
thological studies revealed NSCLC, not otherwise specified (NOS), at clinical stage T3N1M0 stage IIIA. We
started radiotherapy alone because of obstructive pneumonia and end-stage renal disease, but the tumors pro-
gressed rapidly and resulted in death due to air obstruction by pharyngeal metastasis. The cancer was diagnosed
as pleomorphic carcinoma in an autopsy. Viable lung tumor cells, which were resistant to radiotherapy, and the
pharyngeal metastasis had mesenchymal phenotypes and expressed ZEB1 but not SNAI1. These observations
indicated that ZEB1-associated epithelial-mesenchymal transition has malignant features including resistance to
radiotherapy and aggressive metastatic potential. ZEB1-associated EMT may be an important mechanism to
understand the pathophysiology of pleomorphic carcinoma.
1. Introduction
Pleomorphic carcinoma is defined as a poorly differentiated non-
small cell carcinoma (NSCC) that contains at least 10% spindle and/or
giant cells with squamous cell carcinoma, adenocarcinoma, or un-
differentiated NSCC, or a carcinoma consisting only of spindle and giant
cells [1]. These sarcomatoid components are derived from epithelial
components by epithelial-mesenchymal transition (EMT) [2]. Pul-
monary pleomorphic carcinoma has a more aggressive clinical course
compared to that of other non-small cell lung cancer (NSCLC) [3,4].
However, the nature of pleomorphic carcinoma and optimal treatment
remain uncertain because of its rarity.
Pulmonary pleomorphic carcinoma frequently exhibits distant
organ metastasis. The progression to metastatic tumor is particularly
rapid, resulting in a poor prognosis. Moreover, the cancer sometimes
expands into minor organs, such as the gastrointestinal tract, thyroid
gland, peritoneum, or lymph nodes of the abdomen, which cannot be
observed by clinical examination before death [5].
Here, we report a case of pulmonary pleomorphic carcinoma with a
severe malignant phenotype induced by ZEB1-associated EMT.
2. Case report
A 60-year-old man visited the hospital with a complaint of right-side
chest pain. He was diagnosed with NSCLC in the upper right lobe by
trans-bronchial biopsy and admitted. He had chronic kidney disease
due to glomerulonephritis and a smoking history of 70 pack-years.
Blood tests revealed an elevated inflammatory reaction, and marked
disturbance of renal function. Tumor markers, such as cytokeratin
subunit 19 fragment (CYFRA) and pro-gastrin releasing peptide (Pro
GRP), were slightly elevated. Imaging studies revealed a marked en-
largement of the tumor shadow in the upper right lung, with no evi-
dence of distant metastases.
He coughed up a tumor clot, and we performed a pathological ex-
amination with that clot, which consisted of malignant tumor cells with
a high nuclear-to-cytoplasmic ratio (N/C ratio) and acidophilic cyto-
plasm. Pan-cytokeratin was partially positive, but thyroid transcription
factor-1 (TTF-1) and p40 were negative. Therefore, we diagnosed him
with poorly differentiated NSCLC, not otherwise specified (NOS), at
clinical stage T3N1M0 stage IIIA.
He had obstructive pneumonia and exacerbation of renal
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dysfunction, which required hemodialysis. These complications ne-
cessitated radiotherapy (RT) alone, but the right submandibular lymph
nodes metastasis, pharyngeal metastasis, and brain metastasis with
hemorrhage rapidly grew in a few weeks. We discontinued RT and in-
itiated chemotherapy with carboplatin (AUC=2, day 1, 8, 15) and
paclitaxel (40 mg/m2, day 1, 8, 15) every 21 days with local palliative
RT to the cervical and brain metastasis. However, the tumor further
progressed; the pharynx tumor enlargement caused airway obstruction
repeatedly, and the brain metastasis caused symptomatic epilepsy. He
died on day 82 after admission.
We performed an autopsy with his family's consent. We found a
primary lung tumor on the upper right lobe, and metastasis in the brain,
pharynx, larynx, and small intestine macroscopically. Microscopically,
we observed pleomorphic tumor cell proliferations, which contained
both spindle and giant cells. Immunohistochemistry (IHC) revealed
tumor cells that were mostly negative for cytokeratin but strongly po-
sitive for vimentin. Therefore, we diagnosed him with pulmonary
pleomorphic carcinoma.
Most of the lung tumor had necrosis, which was thought to be in-
duced by RT, but we also observed some viable areas. Viable cells has
non-cohesive growth with mesenchymal properties (Fig. 1A). Tumor
cells in the pharynx and small intestine had viable cells similar to the
lung tumor (Fig. 1B and C) and strongly expressed vimentin (Fig. 1E–G)
but not cytokeratin (Fig. 1I–K). On the other hand, tumor cells in the
brain had cohesive proliferation and epithelial properties (Fig. 1D).
Tumor cells in the necrotic area of the lung tumor and in the brain
partially expressed vimentin (Fig. 1H) and cytokeratin (Fig. 1L). These
results suggested that mesenchymal components of pleomorphic car-
cinoma are resistant to RT and induce unusual distant organ metastases,
such as in the pharynx or small intestine.
We analyzed the role of EMT in the patient's tumor because me-
senchymal tumor cells are derived from epithelial cells by EMT in
several types of sarcomatoid carcinoma [2]. IHC showed that ZEB1,
which is a representative EMT marker, was strongly positive (Fig. 2A),
but SNAI1 and E-cadherin were negative (Fig. 2B and C), which sug-
gests that EMT associated with ZEB1 contributes to malignant pheno-
types of pleomorphic carcinoma.
3. Discussion
In general, it is difficult to diagnose pleomorphic carcinoma using
small specimens because of tumor heterogeneity. Although we used a
tumor clot 3 cm in diameter for pathological analysis, the tumor was
poorly differentiated NSCLC (NOS). Because tumor cells were slightly
positive for cytokeratin but not TTF-1 and p40, we did not initially
analyze mesenchymal expression. This case study suggests that pleo-
morphic carcinoma is associated with poorly differentiated carcinoma
with negative or slightly positive epithelial markers.
Metastasis to minor organs is frequently found on autopsies of pa-
tients with pleomorphic carcinoma, but these metastases are difficult to
identify before death. In particular, metastasis to the small intestine is
detrimental because of intestine perforation in some patients [5]. In our
patient, metastasis to the pharynx was the major cause of death because
of airway obstruction. These findings suggest that metastases, espe-
cially to minor organs, is a major factor for patient prognosis. Positron
emission tomography may be useful for investigating metastases to
minor organs, but could not be performed in our patient.
Sarcomatoid carcinoma occurs when various tumor cells,
Fig. 1. Histological findings of the autopsy. Pleomorphic tumor cells had non-cohesive growth with mesenchymal properties in viable areas of the lung tumor (A) and
in metastatic foci of the pharynx (B) and small intestine (C) by hematoxylin-eosin (HE) staining. These tumor cells strongly expressed vimentin (E–G) but not pan-
cytokeratin (I–K). On the other hand, the tumor cells in the brain metastasis had cohesive proliferation with epithelial properties (D), and partially expressed
vimentin (H) and pan-cytokeratin (L). Histological sections are shown at 200×magnification.
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resembling both carcinomas and sarcomas, co-exist in a single tumor.
Clonality analysis has previously shown that sarcoma-like and carci-
noma-like components are derived from a common ancestor in sarco-
matoid carcinoma [2]. In our case, solid proliferations of spindle and
giant cells were observed in the viable area of the lung tumor, and the
metastatic foci of the pharynx and small intestine (Fig. 1B and C).
Moreover, ZEB1 but not SNAI1 was upregulated in these cells (Fig. 2A
and B). EMT is a biological process that converts epithelial cells to
mesenchymal cells, which have a higher potential for migration and
invasion, and resistance to RT and chemotherapy [6]. EMT is induced
by transcriptional factors, such as ZEB1 or SNAI1 [7], which are up-
regulated in several types of cancers including lung cancer [8]. These
results suggest that ZEB1-associated EMT in pleomorphic carcinoma
induces mesenchymal cells from epithelial origins, and contributes to
malignancy, resistance to RT, and aggressive metastasis. However, we
did not detect ZEB1-positive tumor tissues in autopsy samples possibly
because of sample quality. Therefore, we could not evaluate differences
in ZEB1 expression between primary and metastatic tumors.
RT may induce EMT [9], and expression of mesenchymal markers in
clinical NSCLC samples was upregulated after chemoradiotherapy [10].
In our case, the right submandibular lymph nodes metastasis, phar-
yngeal metastasis, and brain metastasis were rapidly enlarged just after
induction of RT. This suggests that RT may have triggered EMT, which
resulted in an aggressive clinical course.
In summary, we observed a rare case of pulmonary pleomorphic
carcinoma with malignant features possibly induced by ZEB1-asso-
ciated EMT. This case highlights the importance of histological analysis
for considering the possibility of pleomorphic carcinoma, and the effect
of metastasis to minor sites. To further understand the role of EMT in
the progression of pleomorphic carcinoma, IHC analysis of more tumor
tissues is needed.
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Fig. 2. The expression of epithelial-me-
senchymal transition (EMT) markers in the
tumor cells of the pharynx metastasis.
Immunohistochemistry showed that ZEB1,
which is a representative EMT marker, was
strongly positive (A), but SNAI1 (B) and E-
cadherin (C) were negative in the me-
senchymal tumor cells. Histological sections
are shown at 200×magnification.
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